Search
Bicycle Therapeutics PLC
BCYCAdd to Watchlist
3.975USD
-0.025-0.63%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
198.23MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Bicycle Therapeutics PLC is 8.00, ranking 164 out of 389 in the Biotechnology & Medical Research industry. The average price target is 16.00, with a high of 44.00 and a low of 6.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
12.778
Target Price
+219.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Bicycle Therapeutics PLC
BCYC
11
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Bicycle Therapeutics PLC's expected revenue for the next quarter?
Bicycle Therapeutics PLC's expected revenue is 4.77M.
What is Bicycle Therapeutics PLC's price target?
Analysts forecast that Bicycle Therapeutics PLC's price target is USD 16.00, with the highest forecast at USD 44.00 and the lowest forecast at USD 6.00.
How have Bicycle Therapeutics PLCBCYC's recent earnings per share performed?
The market expectation was USD -0.87, while Bicycle Therapeutics PLCBCYC's earnings per share (EPS) for the previous quarter was USD -0.29. EPS for the next quarter is expected at USD -0.56.
What is the analyst rating for Bicycle Therapeutics PLC?
Based on the ratings of Bicycle Therapeutics PLC's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
